EN DE
Watch Mabion S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Mabion S.A. (MAB) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Mabion S.A. stock PLN 2.02, price PLN 7.72, that is 73.8% below the price, quality 31 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLMBION00016

MS Mabion S.A. logo Thin data Nov 8, 2026

Mabion S.A.

MAB · WAR
Very expensive, weak quality

Our calculation puts a fair price 74% below what the stock costs today.

Low debt
Profit last quarter 32% below a year ago.
Fair value 2.02 PLN · Strongly overvalued
Quality 31/100
Weak Growth (revenue 3y −54.2 %/yr in PLN)
Negative free cash flow
Trails peers (1/9)
Narrow moat 10/100 · thin data
Thin data
Watch Mabion S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

84.30 PLN 6.82 PLN Fair Value 2.02 PLN Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 6.82 PLN – 84.30 PLN · fair‑value band 1.51 PLN – 3.01 PLN · the 7.72 PLN price screens above the 2.02 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Mabion in your weekly email

Every Wednesday you see whether Mabion is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland.

Show moreShow less

It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services.

In addition, it offers cell line development, process development, production of a product for preclinical and clinical trials, development and validation of analytical methods, and preparation of the necessary documentation.

The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.

Stock analysis

Mabion S.A. (MAB) currently trades at 7.72 PLN, while our model-based Fair Value estimate is 2.02 PLN, 74% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: 1.51 PLN (bear) to 3.01 PLN (bull), the price of 7.72 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Mabion S.A. reported revenue of 15.8M PLN in FY2025 versus 56.9M PLN in FY2021, a compound −27.4%/yr. Reported net income was −62.6M PLN in FY2025.

Key figures

Market cap 125M PLN (≈ $31.9M) Micro · P/S ratio 7.31 · EPS (TTM) −3.51 PLN · Return on equity −108% · Return on assets (EBIT) −2.9% (5-year average) · Operating margin −180% · Revenue (TTM) 17.6M PLN · Revenue growth (YoY) +0.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 20% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −74%, MAB screens richer than that median.

Fair Value models

Bear 1.51 PLN Fair Value 2.02 PLN Bull 3.01 PLN
Price 7.72 PLN · Downside -73.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 1.51 PLN 2.02 PLN 3.01 PLN 54
All 1 models by family
Asset-Based
NCAV (Graham) 1.51 PLN 2.02 PLN 3.01 PLN 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 43
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 77
How calm the share price moves, does not count
Price momentum 40
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 30
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−77.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−54.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.2%
Start year 2020 (pandemic). Over 10 years: +19.1% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,545.5% (2020) → −319.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MAB screens overvalued: fair value 74% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Mabion S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −73.8% · Bottom 25%
Profitability
Return on assets −56.7% · Bottom 25%
Operating margin (12 months) −180.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.1% · Above median
Balance sheet
Debt / equity 0.21× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.56× · Pricier than median
P/S (12 months) 7.08× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)1 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)90 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs MAB
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs MAB
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs MAB
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs MAB
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs MAB
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs MAB
argenx SE ARGX $927.21 $908.40 −2% vs MAB
CSL Limited CSL A$200.77 A$183.04 −9% vs MAB
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs MAB
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs MAB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mabion S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Mabion S.A. Fair Value". https://www.fairvalue-calculator.com/stock/MAB

Frequently asked questions

Is Mabion S.A. (MAB) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 2.02 PLN versus a price of 7.72 PLN, about 74% lower (overvalued).
What is the fair value of MAB?
Our model-based fair value for Mabion S.A. is 2.02 PLN (as of Nov 8, 2026), built from audited fundamentals. The current price: 7.72 PLN.
What is the quality score of MAB?
Mabion S.A. has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mabion S.A. (MAB)?
Our model-based price target is the fair value of 2.02 PLN (as of Nov 8, 2026) from 1 valuation models. Cautious scenario 1.51 PLN, optimistic scenario 3.01 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Mabion S.A. stock forecast for 2026?
Our models put fair value at 2.02 PLN, about 74% lower versus a price of 7.72 PLN (overvalued). Cautious scenario 1.51 PLN, optimistic scenario 3.01 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Mabion S.A. (MAB)?
Mabion S.A. reported trailing-twelve-month revenue of about 17.6M PLN (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Mabion S.A. (MAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mabion S.A. it is 2.02 PLN per share (as of Nov 8, 2026), against a price of 7.72 PLN. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Mabion S.A. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, MAB trades above its calculated fair value: price 7.72 PLN, fair value 2.02 PLN, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MAB?
No. The price is what the market pays today (7.72 PLN); the fair value is what the company's own numbers justify (2.02 PLN). For Mabion S.A. the two are 5.70 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Mabion S.A. worth?
The market values Mabion S.A. at about 125M PLN (market capitalisation, as of Nov 8, 2026). Per share that is 7.72 PLN; our models calculate a fair value of 2.02 PLN per share.
What do the bullish and bearish scenarios say about MAB?
Our models span a range for Mabion S.A.: cautious scenario 1.51 PLN, base 2.02 PLN, optimistic 3.01 PLN per share (as of Nov 8, 2026, price 7.72 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mabion S.A. (MAB)?
Balance-sheet figures for Mabion S.A. (as of Nov 8, 2026): return on equity −107.9%, debt of 0.21 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is MAB from its 52-week high?
Mabion S.A. trades at 7.72 PLN, about 20% below its 52-week high of 9.63 PLN and 13% above the low of 6.82 PLN (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 2.02 PLN is for.
Which stocks are comparable to Mabion S.A.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mabion S.A. stock attractive at the current price?
The data as of Nov 8, 2026: price 7.72 PLN, calculated fair value 2.02 PLN (−74%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MAB calculated?
We run Mabion S.A. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 2.02 PLN builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Mabion S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mabion S.A. (MAB)?
The closing price on Nov 6, 2026 was 7.72 PLN. Our model-based fair value is 2.02 PLN, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mabion S.A. right now?
The price sits above even our optimistic bull case (3.01 PLN). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1.51 PLN to 3.01 PLN) leaves room in how you read the outcome.

Key figures of Mabion S.A.

How large is the market capitalisation of Mabion S.A. (MAB)?
The market capitalisation of Mabion S.A. is 125M PLN (≈ $31.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mabion S.A. (MAB)?
The price-to-sales ratio of Mabion S.A. is 7.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mabion S.A. (MAB)?
Earnings per share at Mabion S.A. are −3.51 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Mabion S.A. (MAB)?
The return on equity (ROE) of Mabion S.A. is −108% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mabion S.A. (MAB)?
On an EBIT basis the return on assets of Mabion S.A. is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mabion S.A. (MAB)?
The operating margin of Mabion S.A. is −180% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mabion S.A. (MAB)?
Revenue at Mabion S.A. is growing +0.1% versus a year earlier (3y avg −54.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mabion S.A. (MAB)?
Earnings per share at Mabion S.A. are growing −31.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Mabion S.A. (MAB) generate?
The free cash flow of Mabion S.A. is −42.5M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Mabion S.A. (MAB) carry?
The net debt of Mabion S.A. is 4.0M PLN (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Mabion S.A. in the live analysis

One click puts Mabion S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.